6. Codexis, Inc. (CDXS): Develops proprietary biocatalysts for pharmaceuticals and biofuels markets. Market cap of $159.0M. Estimated EPS growth over the next 5 years at 25.0%. Net institutional shares purchased over the current quarter at 1.3M, which is 6.21% of the company's 20.92M share float. The stock is a short squeeze candidate, with a short float at 7.02% (equivalent to 8.76 days of average volume). The stock is currently stuck in a downtrend, trading 6.54% below its SMA20, 22.5% below its SMA50, and 50.94% below its SMA200. The stock has performed poorly over the last month, losing 13.54%.
News 
Market Data 
Discover 
